Eleven Biotherapeutics, Inc. (EBIO): Karen L Tubridy , Chief Development Officer of Eleven Biotherapeutics, Inc. sold 4,372 shares on Jun 27, 2016. The Insider selling transaction was reported by the company on Jun 29, 2016 to the Securities and Exchange Commission. The shares were sold at $2.08 per share for a total value of $9,093.76 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 29, 2016, Abbie Celniker (President and CEO) sold 10,029 shares at $2.08 per share price.On Feb 17, 2016, John J Mccabe (Senior Vice President, Finance) sold 1,501 shares at $0.27 per share price.Also, On Dec 30, 2015, Eric Steven Furfine (Chief Scientific Officer) sold 4,652 shares at $2.85 per share price.On Dec 30, 2015, Karen L Tubridy (Chief Development Officer) sold 4,427 shares at $2.85 per share price.
Shares of Eleven Biotherapeutics Inc (EBIO) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.23 points or -10.75% at $1.91 with 13,48,897 shares getting traded. Post opening the session at $2.07, the shares hit an intraday low of $1.82 and an intraday high of $2.14 and the price vacillated in this range throughout the day. The company has a market cap of $38 M and the number of outstanding shares has been calculated to be 1,98,81,725 shares. The 52-week high of Eleven Biotherapeutics Inc is $8 and the 52-week low is $0.2511.
Eleven Biotherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company through AMP-Rx a protein engineering platform is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs engineers and generates a pipeline of protein therapeutic candidates that target cytokines which are central to diseases of the eye. The Company is conducting research and development programs directed at both diseases of the front of the eye such as dry eye disease and allergic conjunctivitis and diseases of the back of the eye such as diabetic macular edema (DME) and uveitis. The Company’s lead product candidate is EBI-005 a cure for dry eye disease and allergic conjunctivitis. Its preclinical product candidates include EBI-031 a cure for DME and EBI-028 a cure for uveitis.